In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…
In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…
In 2022, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $3.6 billion in the major pharmaceutical markets under study (…
In 2022, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.6…
In 2022, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $136 billion in the major pharmaceutical markets under study (United…
In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under…
TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Key treatment goals…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL…
Clarivate Epidemiology’s coverage of the meningococcal B vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis market has been a lucrative space for drug…
Schizophrenia is a psychiatric disease that usually requires long-term treatment. It typically manifests in early adulthood, presenting as a chronic condition characterized by a recurring pattern…